{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:13:54Z","timestamp":1785914034590,"version":"3.56.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are effective across the spectrum of left ventricular ejection fraction (LVEF) in heart failure (HF); however, population-wide medication use in eligible patients remains suboptimal. We evaluated the potential implications of optimal global implementation of SGLT-2 inhibitors in HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A decision analytical study was performed using the global prevalence of HF from the Global Burden of Disease 2017 report. Exclusion criteria were applied using the NHANES to ascertain an SGLT-2 inhibitor-eligible population, which was mapped onto global LVEF distributions from the REPORT-HF registry. The number needed to treat for 3\u2009years for the composite of worsening HF events and cardiovascular deaths was calculated from estimated event rates in the DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER trials and projected onto the eligible population. An estimated 49\u2009329\u2009000 (95% confidence interval [CI] 43\u2009882\u2009000\u201354\u2009929\u2009000) HF patients would be eligible for SGLT-2 inhibitors across all LVEFs, including 25\u2009651\u2009000 (95% CI 22\u2009818\u2009000\u201328\u2009563\u2009000) with LVEF \u226440% and 23\u2009678\u2009000 (95% CI 21\u2009063\u2009000\u201326\u2009366\u2009000) with LVEF &amp;gt;40%. Optimal implementation of SGLT-2 inhibitors would be projected to prevent\/postpone 4\u2009512\u2009011 (95% CI 4\u2009013\u2009686\u20135\u2009024\u2009232) to 5\u2009986\u2009943 (95% CI 5\u2009325\u2009721\u20136\u2009666\u2009604) total worsening HF events and cardiovascular deaths over 3\u2009years in patients with LVEF &amp;lt;40%. An additional 2\u2009102\u2009606 (95% CI 1\u2009870\u2009394\u20132\u2009341\u2009301) to 2\u2009557\u2009224 (95% CI 2\u2009274\u2009804\u20132\u2009847\u2009528) total worsening HF events and cardiovascular deaths would be prevented\/postponed in patients with LVEF &amp;gt;40%. Among all eligible HF patients, irrespective of LVEF, 7\u2009069\u2009235 (95% CI 6\u2009288\u2009490\u20137\u2009871\u2009760) to 8\u2009089\u2009549 (95% CI 7\u2009196\u2009115\u20139\u2009007\u2009905) total worsening HF events and cardiovascular deaths would be prevented\/postponed over this period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Optimal implementation of SGLT-2 inhibitors globally in HF is projected to prevent\/postpone approximately 7\u20138 million worsening HF events and cardiovascular deaths over 3\u2009years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2864","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:10:22Z","timestamp":1681690222000},"page":"999-1009","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Potential Global Impact of Sodium\u2013Glucose Cotransporter-2 Inhibitors in Heart Failure"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-4464","authenticated-orcid":false,"given":"Khawaja M.","family":"Talha","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, and Baim Institute for Clinical Research , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"2026010913101861300_ejhf2864-bib-0001","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913101861300_ejhf2864-bib-0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913101861300_ejhf2864-bib-0003","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913101861300_ejhf2864-bib-0004","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913101861300_ejhf2864-bib-0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913101861300_ejhf2864-bib-0006","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026010913101861300_ejhf2864-bib-0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamacardio.2022.4348","article-title":"Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US","volume":"8","author":"Talha","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026010913101861300_ejhf2864-bib-0008","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913101861300_ejhf2864-bib-0009","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"2026010913101861300_ejhf2864-bib-0010","volume-title":"The Linkage of National Center for Health Statistics Survey Data to the National Death Index \u2013 2015 Linked Mortality File (LMF): Methodology Overview and Analytic Considerations, November 2017","author":"National Center for Health Statistics. Office of Analysis and Epidemiology"},{"key":"2026010913101861300_ejhf2864-bib-0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ejhf.262","article-title":"International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry","volume":"17","author":"Filippatos","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026010913101861300_ejhf2864-bib-0012","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","article-title":"Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study","volume":"8","author":"Tromp","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2026010913101861300_ejhf2864-bib-0013","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-related quality of life and mortality in heart failure: the Global Congestive Heart Failure study of 23 000 patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"2026010913101861300_ejhf2864-bib-0014","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","article-title":"Cardiovascular disease projections in the United States based on the 2020 census estimates","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913101861300_ejhf2864-bib-0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2018.11.005","article-title":"Income inequality and outcomes in heart failure: a global between-country analysis","volume":"7","author":"Dewan","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913101861300_ejhf2864-bib-0016","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/ejhf.2431","article-title":"Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry","volume":"24","author":"Tromp","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913101861300_ejhf2864-bib-0017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.gheart.2019.07.008","article-title":"Access to essential medicines for circulatory diseases: a call to action","volume":"14","author":"McKee","year":"2019","journal-title":"Glob Heart"},{"key":"2026010913101861300_ejhf2864-bib-0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(15)00469-9","article-title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"387","author":"Khatib","year":"2016","journal-title":"Lancet"},{"key":"2026010913101861300_ejhf2864-bib-0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002640","article-title":"Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries","volume":"5","author":"Chow","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2026010913101861300_ejhf2864-bib-0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008971","article-title":"Access to heart failure medicines in low- and middle-income countries: an analysis of essential medicines lists, availability, price, and affordability","volume":"15","author":"Agarwal","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913101861300_ejhf2864-bib-0021","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000438","article-title":"Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review","volume":"3","author":"Banerjee","year":"2016","journal-title":"Open Heart"},{"key":"2026010913101861300_ejhf2864-bib-0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003298","article-title":"Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification","volume":"3","author":"Heneghan","year":"2013","journal-title":"BMJ Open"},{"key":"2026010913101861300_ejhf2864-bib-0023","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/CIRCHEARTFAILURE.121.009099","article-title":"Out-of-pocket costs for SGLT-2 (sodium-glucose transport protein-2) inhibitors in the United States","volume":"15","author":"Aggarwal","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913101861300_ejhf2864-bib-0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamacardio.2022.5033","article-title":"Estimation of out-of-pocket costs for guideline-directed medical therapy for heart failure under Medicare Part D and the Inflation Reduction Act","volume":"8","author":"Johnson","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"Suppl 1","key":"2026010913101861300_ejhf2864-bib-0025","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2026010913101861300_ejhf2864-bib-0026","volume-title":"Model List of Essential Medicines \u2013 22nd list","author":"World Health Organization","year":"2021"},{"key":"2026010913101861300_ejhf2864-bib-0027","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913101861300_ejhf2864-bib-0028","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jchf.2023.01.004","article-title":"Cost-effectiveness of comprehensive quadruple therapy for heart failure with reduced ejection fraction","volume":"11","author":"Dixit","year":"2023","journal-title":"JACC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/7\/999\/65494575\/eurjhf_25_7_999.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/7\/999\/65494575\/eurjhf_25_7_999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:12:51Z","timestamp":1767982371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/7\/999\/8341881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2864","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"2023-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}